drugset
drugset / Trial / NCT00857961

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

NCT00857961 ↗

Phase 2 Completed 21 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product.

Timeline

Start
2007-10
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 30 mg Topical
Subject Testosterone Small molecule 60 mg Topical
Subject Testosterone Small molecule 90 mg Topical

Indications

hypogonadism, male